Trial Profile
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipatasertib (Primary) ; Abiraterone; Abiraterone acetate; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms IPATential150
- Sponsors Chugai Pharmaceutical; Roche
- 08 Mar 2024 This study has been completed in France and Portugal, according to European Clinical Trials Database record.
- 12 Feb 2024 Planned End Date changed from 31 Dec 2023 to 30 Apr 2024.
- 03 Feb 2024 This trial has been Completed in Poland, According to European Clinical Trials Database record.